The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety assessed by adverse events: Part 1
Timeframe: Up to Day 7
Safety assessed by adverse events: Part 2
Timeframe: Up to Day 22
Safety assessed by vital signs: Part 1
Timeframe: Up to Day 7
Safety assessed by vital signs: Part 2
Timeframe: Up to Day 22
Safety assessed by clinical laboratory test: Part 1
Timeframe: Up to Day 7
Safety assessed by clinical laboratory test: Part 2
Timeframe: Up to Day 22
Safety assessed by 12-Lead ECG: Part 1
Timeframe: Up to Day 7
Safety assessed by 12-Lead ECG: Part 2
Timeframe: Up to Day 22